Financial Performance - The company's revenue for the six months ended June 30, 2022, was RMB 16,569 million, a decrease of 9.5% compared to RMB 18,310 million in the same period last year[6]. - Gross profit for the same period was RMB 8,596 million, down 18.7% from RMB 10,578 million year-on-year[6]. - The operating loss for the period was RMB 3,047 million, compared to an operating profit of RMB 1,260 million in the previous year[6]. - The net loss attributable to the company's owners was RMB 7,084 million, compared to a loss of RMB 312 million in the same period last year[10]. - The total comprehensive loss for the period was RMB 7,421 million, compared to a comprehensive income of RMB 239 million in the previous year[6]. - The total profit from external customers for the six months ended June 30, 2022, was RMB 5,814,000, down 33.5% from RMB 8,697,000 in the previous year[42]. - The company reported a pre-tax loss of RMB 1,436,000 for the six months ended June 30, 2022, compared to a profit of RMB 4,711,000 in the same period of 2021[42]. - The company reported a loss attributable to owners of RMB 6,362,000, compared to a profit of RMB 2,345,000 in the previous period[138]. Cash Flow and Assets - The company's cash and bank balances increased to RMB 125,138 million from RMB 117,557 million year-on-year[12]. - Non-current assets, including property, plant, and equipment, were valued at RMB 32,296 million, up from RMB 25,191 million in the previous year[12]. - The total assets less current liabilities amounted to RMB 146,422 million, compared to RMB 133,677 million in the previous year[12]. - The total cash and cash equivalents as of June 30, 2022, amounted to RMB 125,138,000, slightly down from RMB 125,616,000 at the beginning of the period[19]. - The cash and cash equivalents increased by RMB 8,059,000 during the six months ended June 30, 2022, compared to a decrease of RMB (815,000) in the same period of 2021[19]. - As of June 30, 2022, net trade receivables amounted to RMB 935,000, a 113% increase from RMB 439,000 as of December 31, 2021[94]. - The net amount of prepayments, deposits, and other receivables was RMB 30,072,000, a slight decrease from RMB 31,291,000[94]. Revenue Breakdown - Total revenue for the first half of 2022 was RMB 37,149,000, a slight decrease of 0.33% compared to RMB 37,271,000 in the same period of 2021[34]. - Revenue from funeral services and cremation services was RMB 35,061,000, down 1.30% from RMB 35,521,000 in the previous year[34]. - Revenue from funeral arrangements and related consulting services increased to RMB 1,482,000, up 34.55% from RMB 1,101,000 in the previous year[34]. - Sales of burial plots and tombstones rose to RMB 404,000, significantly up from RMB 144,000 in the previous year[34]. - Revenue from stem cell and immune cell consulting services decreased to RMB 202,000, down 60% from RMB 505,000 in the previous year[34]. - Revenue from the Chinese market was approximately RMB 35,061,000, a decrease of about 2.7% compared to the previous period's RMB 36,026,000[129]. - Revenue from Taiwan increased by 13.3% to approximately RMB 717,000, driven by fewer COVID-19 restrictions[132]. - Revenue from Hong Kong surged by approximately 106.6% to RMB 967,000, with new stem cell and immune cell consultation services generating RMB 202,000[132]. - Revenue from Vietnam rose significantly by 180.6% to RMB 404,000, attributed to the resumption of operations after previous lockdowns[134]. Expenses and Costs - Cost of sales increased by approximately 10.1% to RMB 17,136,000, primarily due to higher employee costs and one-time bonuses during the COVID-19 pandemic[135]. - Administrative expenses rose by approximately 39.1% to RMB 19,139,000, accounting for 51.5% of revenue, due to increased wage levels and special bonuses[137]. - Employee costs, including director remuneration, increased to RMB 15,640,000 from RMB 10,965,000, representing a rise of 42.5%[67]. - Financing costs decreased to RMB 982,000 from RMB 1,169,000, reflecting a reduction of 16%[42]. Investments and Financial Position - The group held financial assets measured at fair value totaling RMB 48,091,000 as of June 30, 2022, compared to RMB 38,577,000 as of December 31, 2021[89]. - The group held significant investments in equity securities listed outside Hong Kong amounting to RMB 15,082,000 as of June 30, 2022, compared to RMB 4,093,000 on December 31, 2021[146]. - The group recorded a net gain of approximately RMB 1,490,000 from realized and unrealized gains on financial assets measured at fair value during the period, compared to a net loss of RMB 37,000 in the previous period[92]. - The group has no significant acquisitions or disposals of investments during the reporting period[147]. Corporate Governance and Compliance - The financial statements are prepared in accordance with the GEM Listing Rules and Hong Kong Financial Reporting Standards[22]. - The board of directors has confirmed compliance with the corporate governance code as per GEM listing rules during the reporting period[191]. - An audit committee has been established, consisting of three independent non-executive directors, to review and monitor the financial reporting process and internal control systems[197]. - The audit committee reviewed the unaudited condensed consolidated financial statements for the period and confirmed compliance with applicable accounting standards[197]. - The company failed to comply with GEM listing rules regarding financial reporting due to travel restrictions in Taiwan and Vietnam related to COVID-19, impacting the audit of the financial statements for the year ended December 31, 2021[195]. Strategic Focus and Future Plans - The company has established a business structure focused on traditional funeral services and emerging biotechnology, with a long-term strategic emphasis on biotechnology[125]. - The company is primarily involved in stem cell applications and high-end biotechnology instruments, achieving substantial progress in these areas[125]. - The group plans to allocate more resources to support the development of its biotechnology business and actively seek suitable investment opportunities[159]. - The group is currently evaluating the impact of new accounting standards, with preliminary results indicating no significant effect on financial performance[32]. Shareholder Information - Mr. Xu Jianchun holds 220,475,000 shares, representing approximately 29.69% of the total issued shares[161]. - Dr. Xu Qiang and Mr. Sun Fei each hold 3,712,000 shares, accounting for 0.50% of the total issued shares[161]. - Mr. Xu Jianchun has a direct beneficial interest of 25.55% in Hong Kong Gaoqi and an additional 9.78% interest through HBT Limited[161]. - HBT Limited is registered in the British Virgin Islands and has two classes of shares, with different voting rights[161]. - Mr. Xu Jianchun controls 86.78% of the total voting rights in HBT Limited[161].

Financial Performance - The revenue for the three months ended March 31, 2022, was RMB 20,580,000, compared to RMB 18,961,000 for the same period in 2021, representing an increase of approximately 8.5%[4] - The gross profit for the same period was RMB 11,417,000, slightly up from RMB 11,123,000 in the previous year, indicating a growth of about 2.6%[4] - Operating profit decreased to RMB 2,593,000 from RMB 4,620,000 year-on-year, reflecting a decline of approximately 43.9%[4] - Profit before tax was RMB 2,093,000, down from RMB 3,975,000 in the prior year, marking a decrease of around 47.4%[4] - The net profit attributable to the owners of the company for the period was RMB 722,000, compared to RMB 2,657,000 in the same period last year, a decline of approximately 72.8%[15] - The company reported total comprehensive income of RMB (19,000) for the period, compared to RMB 3,787,000 in the previous year, indicating a significant drop[13] - Administrative expenses increased to RMB 6,505,000 from RMB 5,615,000, representing an increase of about 15.8%[4] - The company incurred financing costs of RMB 500,000, down from RMB 645,000, showing a reduction of approximately 22.5%[4] - Other income and gains netted a loss of RMB 1,548,000, compared to a gain of RMB 411,000 in the previous year, indicating a significant decline[4] - The company's basic earnings per share for the three months ended March 31, 2022, were RMB 0.10, a decrease of 72.2% from RMB 0.36 in the same period last year[50] Revenue Breakdown - Revenue from funeral services and cremation services was RMB 19,354,000, compared to RMB 18,210,000 in the previous year, reflecting an increase of about 6.3%[39] - The group recorded sales of cemetery plots and tombstones amounting to RMB 243,000, up from RMB 119,000 in the prior year, indicating a growth of approximately 104.2%[39] - Revenue from stem cell and immune cell consultation services was RMB 144,000, which was a new revenue stream introduced this year[39] - Revenue from external customers in China was RMB 19,354,000, an increase from RMB 18,210,000 in the previous year, showing a growth of about 6.3%[41] - Revenue from Taiwan was RMB 400,000, slightly up from RMB 396,000 in the previous year, indicating a growth of approximately 1%[41] - Revenue from Hong Kong increased to RMB 583,000 from RMB 236,000, representing a significant growth of about 146.2%[41] - Revenue from Vietnam rose to RMB 243,000 from RMB 119,000, marking an increase of approximately 104.2%[41] - The group’s revenue from Taiwan was approximately RMB 400,000, reflecting a year-on-year increase of about 1.0%[59] - Sales from cemetery services in Vietnam amounted to approximately RMB 243,000, representing a year-on-year increase of about 104.2% from RMB 119,000[60] Strategic Focus and Investments - The company continues to focus on expanding its services in China, Taiwan, and Hong Kong, as well as exploring opportunities in Vietnam for cemetery and related services[26] - The group has established a specialized investment platform focused on biotechnology, including biomedicine and life science instruments, to drive rapid business development[54] - The company plans to reduce investment in stem cell business in the short term due to regulatory constraints in mainland China[53] - The group aims to leverage resource advantages to expand its high-end biotechnology instrument business in response to the rapid development of the electronic microscope industry in mainland China[53] - The company is focusing on the development of biotechnology, with significant progress in sales of life science instruments[69] - The company plans to increase its investment in biotechnology and seek suitable investment opportunities to maximize returns for shareholders[72] Financial Management and Compliance - The company has invested a total of RMB 18,428,000 in joint ventures and construction projects as of March 31, 2022[65] - The company maintains a prudent financial management strategy to ensure adequate liquidity for operations and potential acquisitions[65] - The group has adopted new and revised accounting standards, which are not expected to have a significant impact on the financial statements[36] - The financial statements are prepared based on historical cost, with certain assets measured at fair value, including investment properties and financial assets[29] - The company faced delays in publishing its audited financial results for the year ended December 31, 2021, due to travel restrictions related to COVID-19, resulting in non-compliance with GEM listing rules[95] - The company published its preliminary unaudited full-year results for 2021 on March 30, 2022, following the guidelines provided for COVID-19 related delays[97] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the period and confirmed compliance with applicable accounting standards[98] Shareholding and Governance - As of March 31, 2022, Mr. Xu holds 220,475,000 shares, representing approximately 29.69% of the total issued share capital of the company[76] - Mr. Xu has a direct beneficial interest of 25.55% in Hong Kong Gaoqi Biotechnology Co., Ltd. and a 9.78% interest in Houp Bio-Technology Limited[78] - HBT Limited has two classes of shares, with A shares having 30 votes per share and B shares having 1 vote per share[78] - Mr. Xu controls 94.07% of the A shares in HBT Limited, giving him a total voting power of 86.78% in HBT Limited[78] - Ms. Qiu holds 5.93% of the A shares and 10.74% of the B shares in HBT Limited, which are considered under Mr. Xu's interest[82] - No other directors or senior executives have disclosed any interests or short positions in the company's shares or related securities as of March 31, 2022[79] - Hong Kong Gaoqi holds 220,475,000 shares, also representing approximately 29.69% of the total issued share capital[81] - There are no significant transactions or contracts involving directors or their related entities during the reporting period[85] - The company has not entered into any management or administrative contracts for its business during the reporting period[88] - The company established a capital increase agreement and joint venture agreement on September 13, 2021, which was approved by shareholders on November 22, 2021[89] - The joint venture will engage in equity and/or securities investment business, while the partner will focus on technology development, consulting services, investment activities, and business management consulting[89]

Financial Performance - The revenue for the year ended December 31, 2021, was approximately RMB 72,864,000, representing a year-on-year increase of 6.6% compared to RMB 68,340,000 for the prior year[18]. - Revenue from the Taiwan market decreased to approximately RMB 1,450,000, a year-on-year decline of 32.5% from RMB 2,148,000 due to strict pandemic control measures[21]. - In Hong Kong, revenue from funeral arrangement and related consultancy services increased to approximately RMB 892,000, representing a year-on-year growth of 82.8% from RMB 488,000[21]. - The Group's revenue from the PRC market increased by 14.6% year-on-year to approximately RMB 70,294,000 from RMB 61,317,000 in the prior year[48]. - Revenue from funeral, cremation, and cemetery services in the PRC contributed approximately RMB 69,561,000, up from RMB 60,961,000 in the prior year[49]. - Revenue from Vietnam decreased by approximately 47.6% to RMB 228,000 from RMB 435,000 in the prior year[57]. - Gross profit for the year was approximately RMB 37,977,000, a year-on-year increase of 30.2%, with a gross profit margin of approximately 52.1% compared to 42.7% in the prior year[68]. - The increase in gross profit was mainly driven by the funeral services in China, which rebounded from the impact of COVID-19[68]. - The Group's funeral services in the PRC rebounded from the impact of COVID-19, benefiting from the recovery of economic activities[50]. - Loss attributable to the owners of the Company for the year was approximately RMB 9,872,000, compared to RMB 2,974,000 in the prior year, with loss per share of approximately RMB 1.33 cents[77]. Business Strategy and Focus - The Group's business pattern focuses on traditional funeral services and emerging biotechnology, with traditional funeral services accounting for a large proportion of the Group's business[18]. - The Group is focusing on biotechnology as a long-term business expansion strategy, particularly in stem cells and advanced biotechnical equipment[23]. - A specialized investment platform was established in December 2021 to promote the rapid development of the biotechnology business, focusing on biomedicine, medical healthcare, and life science instruments[25]. - The Group aims to allocate more resources to support the development of its biotechnology business while consolidating its traditional funeral services[26]. - The Group plans to reduce investments in the stem cell business in the short term due to the lack of large-scale development opportunities in Mainland China[23]. - The Group aims to expand its advanced biotechnical equipment business by leveraging opportunities in the rapidly developing electron microscope industry in Mainland China[42]. - The Group positions Zhongke Zhenhui as a specialized investment platform for biotechnology development, including biomedicine and medical healthcare[104]. - The Group will continue to monitor the impact of the COVID-19 pandemic on its financial position and operating results[79]. Economic Environment - China's GDP reached RMB 114.4 trillion in 2021, with a real GDP growth rate of 8.1%[17]. - The economic development in China is led by strategic emerging industries such as new energy, intelligent manufacturing, biomedicine, and semiconductors[17]. - The Chinese government established the Beijing Stock Exchange in November 2021 to expand financing channels for small and medium-sized enterprises, promoting innovative development in emerging industries[36]. - The ongoing COVID-19 pandemic continues to create uncertainty in the global economic environment, affecting customer spending and business operations[98]. - The strategic goals of supporting emerging industries and promoting high-quality economic development in China remain unchanged despite economic pressures[102]. Corporate Governance - The Company will review its corporate governance practices to ensure compliance with statutory requirements and the GEM Listing Rules[116]. - The Company emphasizes the importance of management reporting to the Board before making significant decisions or commitments[128]. - The Board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with defined terms of reference[150]. - The Company has maintained compliance with GEM Listing Rules regarding Directors' securities transactions throughout the year[120]. - The Board consists of six Directors, demonstrating diversity in age, service length, educational background, and professional experience[198]. - The Nomination Committee believes the current Board composition meets measurable objectives for achieving diversity[200]. Human Resources - The Group employed approximately 171 employees as of December 31, 2021, a decrease from 179 employees in the prior year[91]. - The Group will implement various incentives to attract and retain top talents to improve operational conditions and enhance profitability[111]. - The attendance record for Directors at meetings indicates full participation from executive Directors[136]. Financial Position - As of December 31, 2021, the Group had cash and bank balances of approximately RMB 117,557,000, with current and non-current bank borrowings of approximately RMB 1,192,000 and RMB 4,812,000 respectively[77]. - The gearing ratio as of December 31, 2021, was approximately 2.3%, a slight decrease from 2.5% in the prior year[77]. - The Group did not use any financial instruments for hedging purposes during the year, maintaining a prudent financial management strategy[77]. - The Group's capital expenditure for property, plant, and equipment in 2021 amounted to approximately RMB 1,303,000, down from RMB 3,713,000 in the prior year[95]. - The Group's financial condition may be affected by changes in exchange rates of RMB against USD, NTD, HKD, and VTD[79].

8 於開發群島註冊成立的有限公司 股份代號:8296 JLLEST SINO LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 2020 第三季度報告 H2( 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料；本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所 ...

Financial Performance - For the six months ended June 30, 2019, the company reported total revenue of RMB 31,705,000, an increase of 0.62% compared to RMB 31,509,000 for the same period in 2018[7]. - The gross profit for the same period was RMB 16,047,000, representing a gross margin of 50.6%, compared to RMB 15,309,000 and a gross margin of 48.7% in 2018[7]. - The company incurred a loss of RMB 1,969,000 for the six months ended June 30, 2019, an improvement from a loss of RMB 2,577,000 in the prior year[9]. - Basic and diluted loss per share for the six months was RMB 0.03, compared to a loss of RMB 0.39 per share in the same period of 2018[9]. - The total comprehensive income for the period, after tax, was RMB 622,000, compared to RMB 3,406,000 in the previous year[9]. - The company reported a net profit before tax of RMB 201 thousand for the six months ended June 30, 2019, a significant recovery from a loss of RMB 2,504 thousand in the same period of 2018[62]. - The group recorded a profit attributable to owners of approximately RMB 242,000, compared to a loss of RMB 2,869,000 in the previous period, resulting in earnings per share of RMB 0.03 compared to a loss of RMB 0.39 per share previously[143]. Cash Flow and Liquidity - Cash and cash equivalents as of June 30, 2019, amounted to RMB 115,764,000, a decrease from RMB 205,272,000 at the end of 2018[12]. - The company reported a net cash outflow from operating activities of RMB (2,565) thousand for the six months ended June 30, 2019, compared to RMB (2,364) thousand for the same period in 2018[22]. - The net cash inflow from investing activities was RMB 14,146 thousand for the six months ended June 30, 2019, compared to a net outflow of RMB (437) thousand in 2018[22]. - The company experienced a net cash outflow from financing activities of RMB (355) thousand in the first half of 2019, an improvement from RMB (967) thousand in the same period of 2018[22]. - The total cash and cash equivalents increased by RMB 11,226 thousand to RMB 115,764 thousand as of June 30, 2019, compared to RMB 101,345 thousand at the end of June 2018[22]. - The group maintained a healthy financial position with cash and bank balances of approximately RMB 115,764,000 as of June 30, 2019, up from RMB 103,467,000 at the end of 2018[145]. Assets and Liabilities - The company's total assets less current liabilities stood at RMB 149,700,000, an increase from RMB 111,043,000 in the previous year[12]. - The company’s total liabilities as of June 30, 2019, were RMB (161,984) thousand, reflecting a significant increase from RMB (153,297) thousand in the previous year[18]. - The total assets of the company as of June 30, 2019, were RMB 255,074 thousand, up from RMB 227,661 thousand as of December 31, 2018, showing an increase of approximately 12.06%[59]. - The total liabilities increased to RMB 160,228 thousand as of June 30, 2019, from RMB 123,818 thousand at the end of 2018, marking a rise of about 29.43%[59]. - The company’s lease liabilities include both current and non-current portions, with current lease liabilities amounting to RMB 4,178,000 and non-current lease liabilities at RMB 38,249,000[47]. Business Strategy and Future Outlook - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming periods[6]. - The company is focused on expanding its services in the funeral and related sectors, as well as in the sale of burial plots and tombstones, which are key areas for future growth[24]. - The company has introduced a new business segment focused on stem cell and immune cell services, which is expected to be a major value driver[54]. - The company plans to continue its focus on the funeral business while actively developing the cell industry through various investment collaborations[157]. - The company aims to create value for shareholders by seeking new business opportunities and optimizing its business structure for sustainable growth[157]. Accounting and Financial Reporting - The board of directors confirmed that the financial information presented is accurate and complete, with no misleading elements[2]. - The adoption of Hong Kong Financial Reporting Standard 16 resulted in an increase of RMB 31,513 thousand in right-of-use assets and a total lease liability of RMB 40,363 thousand as of June 30, 2019[36]. - The financial impact of HKFRS 16 did not have a significant effect on the earnings per share for the period[38]. - The total equity decreased by RMB 11,648 thousand due to the adjustments made under HKFRS 16[36]. - The audit committee, composed of three independent non-executive directors, reviewed the financial statements for the six months ended June 30, 2019, and confirmed compliance with applicable accounting standards[188]. Revenue Breakdown - The revenue from funeral services was RMB 29,958 thousand, an increase from RMB 29,234 thousand in the previous year, reflecting a growth of about 2.48%[74]. - The revenue from stem cell and immune cell sales was RMB 301 thousand for the six months ended June 30, 2019, compared to no revenue in the same period of 2018[67]. - Revenue from the sale of burial plots and tombstones was RMB 175 thousand for the six months ended June 30, 2019, up from RMB 123 thousand in the same period of 2018, indicating a growth of approximately 42.24%[67]. - The group's revenue from the Chinese funeral services business increased by approximately 2.5% compared to the same period last year, reaching RMB 29,958,000, which accounts for 94.5% of total revenue[134]. - Revenue from the Taiwan market decreased by approximately 8.3%, totaling RMB 1,308,000, representing 4.1% of total revenue[139]. - Revenue from the Hong Kong market saw a significant decline of 63.2%, amounting to RMB 264,000, which is 0.8% of total revenue[139]. Cost Management - Employee costs, including director remuneration, rose to RMB 9,583,000 for the six months ended June 30, 2019, up from RMB 7,991,000 in 2018, reflecting a 20% increase[79]. - Sales costs decreased by approximately 3.3% to about RMB 15,658,000 from RMB 16,200,000, attributed to cost control measures in funeral services[142]. - Administrative expenses were approximately RMB 9,484,000, down about 15.8% from RMB 11,261,000, reflecting effective cost control measures[142]. Shareholder Information - As of June 30, 2019, Hong Kong Gaoqi holds 220,475,000 shares, representing approximately 29.69% of the company's issued share capital[160]. - The weighted average number of ordinary shares for the six months ended June 30, 2019, remained unchanged at 742,500,000 shares[91]. - The stock option plan allows for a maximum of 74,250,000 shares to be issued, equivalent to 10% of the total issued shares as of the mid-term report date[171]. - The total number of shares that may be issued under the stock option plan and any other plans shall not exceed 30% of the total issued shares at any time[173].

活出精彩 Live life to the Fulle GROUP LIMITED SINO-LIFE 中國生命集團有 限 公 司 於開曼群島註冊成立的有限公司 股份代號:8296 2019 第一李度報告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所的GEM證券上市規則（「GEM上市規則」）而刊 載，旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董 事（「董事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢 ...